AATHEN is a multi-disciplinary, multi-Centre and multi-Faculty network that will benefit from the applicants’ broad expertise in ARB chemistry, pharmacology and disease modeling to jump-start synergistic collaboration on the therapeutic use of ARBs, increase ARB-related funding and competitiveness of grant proposals on ARBs, facilitate technological development leaps though screening of novel ARB-like compounds created at UBC, and identify new BP-independent biomarkers for therapeutic purposes.
The UBC Applicants span several sites, including the UBC Point Grey and Okanagan campuses, St. Paul’s Hospital Heart + Lung Innovation Centre, BC Children’s Hospital Research Institute, the Djavad Mowafaghian Centre for Brain Health and the BC Cancer Agency Research Centre. The Applicants are affiliated with the UBC-V Faculty of Medicine, Faculty of Science and the UBC-O Faculty of Health and Social Development.
All Applicants have documented expertise in their respective disease or commercialization of ARBs. The Applicants are committed to offer AATHEN their research expertise, trainees, infrastructure, existing preclinical disease models and patient cohorts to support ARB technological developments, ensure AATHEN sustainability through collaboration, knowledge translation, additional peer-reviewed and private funding, efficient screening of potential lead compounds, future clinical testing and most importantly development of a local web of knowledge on ARBs through seminars from external speakers, brainstorming sessions and in-person/virtual meetings.
